Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder

Psychiatry Investigation

Volumn 5, Issue 2, 2008, Pages 102-105

  Yun, Dong Hwan ^a   Pae, Chi Un ^a,b   Drago, Antonio ^c   Mandelli, Laura ^c   De Ronchi, Diana ^c   Patkar, Ashwin A ^b   Paik, In Ho ^a   Serretti, Alessandro ^c   Kim, Jung Jin ^a  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antimanic agents; Bipolar disorder; Dysbindin; Pharmacogenetics

Indexed keywords

CARBAMAZEPINE; DYSBINDIN; LITHIUM; MOOD STABILIZER; TRANQUILIZER; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR I DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DYSBINDIN GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; TREATMENT RESPONSE; YOUNG MANIA RATING SCALE;

EID: 46949101020     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2008.5.2.102     Document Type: Article

References (27)

1. Althoff RR, Faraone SV, Rettew DC, Morley CP, Hudziak JJ. Family, twin, adoption, and molecular genetic studies of juvenile bipolar disorder. Bipolar Disord 2005;7:598-609.
2. Savitz JB, Cupido CL, Ramesar RS. Trends in suicidology: personality as an endophenotype for molecular genetic investigations. PLoS Med 2006;3:e107.
3. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004;161:780-796.
4. Savitz J, Solms M, Ramesar R. Neuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord 2005;7:216-235.
5. Zhou R, Zarate CA, Manji HK. Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profiling. Int J Neuropsychopharmacol 2006;9:263-266.
6. Benson MA, Newey SE, Martin-Rendon E, Hawkes R, Blake DJ. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem 2001:276:24232-24241.
7. lizuka Y, Sei Y, Weinberger DR, Straub RE. Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J Neurosci 2007;27:12390-12395.
8. Practice guideline for the treatment of patients with bipolar disorder. Amerian Psychiatric Association. Am J Psychiatry 1994;151:1-36.
9. Kleindienst N, Engel RR, Greil W. Psychosocial and demographic factors associated with response to prophylactic lithium: a systematic review for bipolar disorders. Psychol Med 200535:1685-1694.
10. Ruzickova M, Turecki G, Alda M. Pharmacogenetics and mood stabilization in bipolar disorder. Am J Med Genet C Semin Med Genet 2003; 123C:18-25.
11. Rowe MK, Chuang DM. Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 2004;6:1-18.
12. Alda M, Grof P, Rouleau GA, Turecki G, Young LT. Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder. Prog Neuropsychopharmacol Biol Psychi- atry 2005;29:1038-1045.
13. Rao JS, Ertley RN, Rapoport SI, Bazinet RP, Lee HJ. Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. J Neurochem 2007;102:1918-1927.
14. Kazuno AA, Munakata K, Tanaka M, Kato N, Kato T. Relationships between mitochondrial DNA subhaplogroups and intracellular calcium dynamics. Mitochondrion 2008;8:164-169.
15. Einat H. Modelling facets of mania-new directions related to the notion of endophenotypes. J Psychopharmacol 2006;20:714-722.
16. Kishimoto M, Ujike H, Motohashi Y, Tanaka Y, Okahisa Y, Kotaka T, et al. The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol Psychiatry 2008;63:191-196.
17. Duan J, Martinez M, Sanders AR, Hou C, Burrell GJ, Krasner AJ, et al. DTNBP1 (Dystrobrevin binding protein 1) and schizophrenia: association evidence in the 3′ end of the gene. Hum Hered 2007;64: 97-106.
18. Pae CU, Serretti A, Mandelli L, De Ronchi D, Patkar AA, Jun TY, et al. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenet Genomics 2007;17:69-75.
19. Schwab SG, Knapp M, Mondabon S, Hallmayer J, Borrmann-Hassenbach M, Albus M, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet 2003;72:185-190.
20. th edition (DSM-IV). Washington. DC; American Psychiatric Association; 1994.
21. Yildiz-Yesiloglu A, Ankerst DP. Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:969-995.
22. Kugaya A, Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 2005;10:808-819.
23. Abelli M, Martini C, Pini S, Gesi C, Cassano GB. The role of newer antiglutamatergic agents as mood-stabilizers in bipolar disorder. Curr Drug Targets 2005;6:607-614.
24. Goodnick PJ. Anticonvulsants in the treatment of bipolar mania. Expert Opin Pharmacother 2006;7:401-410.
25. Pae CU, Serretti A, Mandelli L, Yu HS, Patkar AA, Lee CU, et al. Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:701-703.
26. Raybould R, Green EK, MacGregor S, Gordon-Smith K, Heron J, Hyde S, et al. Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry 2005;57:696-701.
27. Zill P, Baghai TC, Engel R, Zwanzger P, Schüle C, Eser D, et al. The dysbindin gene in major depression: an association study. Am J Med Genet B Neuropsychiatr Genet 2004;129B:55-58.